𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma

✍ Scribed by Himelstein, Bruce P.; Asada, Naohiro; Carlton, Martha R.; Collins, Margaret H.


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
520 KB
Volume
31
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


Background. Over 80% of patients with osteosarcoma treated with excision alone develop pulmonary metastases, suggesting that the majority of patients with this disease harbor ''micrometastases'' at diagnosis. There are no histologic or molecular variables which can predict the presence or absence of micrometastasis. Matrix metalloproteinases (MMPs) are a class of matrix-and basement membranedegrading enzymes whose expression is associated with tumor cell invasive and metastatic behavior. One of these enzymes, MMP-9 or gelatinase B, is expressed in developing and remodeling bone and in osteosarcoma cell lines. We speculated that MMP-9 expression might be associated with the micrometastatic behavior of osteosarcoma. Procedure. We ex-amined a series of pediatric primary osseous osteosarcomas and metastases for the expression of MMP-9, using a monoclonal antibody. Results. We found intense MMP-9 immunostaining in most tumor cells in all samples of pretreatment osteosarcomas. In all postchemotherapy resection samples, tumor cells stained similarly, but there were fewer positively staining cells overall. In 4 of 5 metastastic lesions examined, intense immunostaining for MMP-9 was detected. Conclusions. These results suggest that MMP-9 expression is common in osteosarcoma, and that further study of the role of MMP-9 in pediatric osteosarcoma behavior is warranted. Med.


πŸ“œ SIMILAR VOLUMES


Cytokines and signaling pathways regulat
✍ Gabriel M. Gordon; Dolena R. Ledee; William J. Feuer; M. Elizabeth Fini πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 395 KB

## Abstract Matrix metalloproteinase‐9 (MMP‐9) is a well‐known regulator and effecter of many cellular processes including wound healing. In the cornea, either too much or too little MMP‐9 can be detrimental to overall wound repair. We investigated the secreted factors as well as the intracellular

Matrix metalloproteinase (MMP)-12 regula
✍ Hwanhee Oh; Siyoung Yang; Meeyoung Park; Jang-Soo Chun πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 257 KB

## Abstract Limited information is available on the expression and role of matrix metalloproteinase (MMP)‐12 in chondrocytes. We characterized the expression mechanism of MMP‐12 and possible function in chondrocytes. Interleukin (IL)‐1Ξ² induced the expression and activation of MMP‐12 in primary cul

Expression of Mmp-9 and related matrix m
✍ Eric V. Yang; David M. Gardiner; Marc R.J. Carlson; Cherryl A. Nugas; Susan V. B πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 351 KB πŸ‘ 2 views

One of the earliest events in limb regeneration is the extensive remodeling of the extracellular matrix (ECM). Matrix metalloproteinases (MMPs) are a family of matrix degrading enzymes that have been identified in both normal and disease states. Using RT-PCR and cDNA library screening, we have isola

Intermittent administration of parathyro
✍ P. McClelland; J.E. Onyia; R.R. Miles; Y. Tu; J. Liang; A.K. Harvey; S. Chandras πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 573 KB

Intermittent doses of parathyroid hormone (PTH) stimulate bone formation in animals and humans, but the molecular mechanisms underlying this phenomenon are not understood. Bone formation culminates with the expression of type I collagen, osteocalcin, and alkaline phosphatase, but genes that initiate

Vascular endothelial growth factor expre
✍ Carine Munaut; AgnΓ¨s NoΓ«l; Olivier Hougrand; Jean-Michel Foidart; Jacques Bonive πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 340 KB πŸ‘ 1 views

Vascular endothelial growth factor (VEGF) is the major endothelial mitogen in central nervous system neoplasms and it is expressed in 64-95% of glioblastomas (GBMs). Tumour cells are the main source of VEGF in GBMs whereas VEGF receptors (VEGFR-1, its soluble form sVEGFR-1, VEGFR-2 and neuropilin-1)